ArticleFrontiers in pharmacology2026
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD) is a common microvascular complication of diabetes. Current treatments for DKD are limited and associated with side effects. Purpose: Investigating the Pharmacological Effects and Mechanisms of Methods: Using db/db mice as an Results: Treatment with AVLE significantly reduced proteinuria, renal pathological damage, and fibrosis in db/db mice and mitigated HG-induced injury in HK-2 cells. A total of 60 metabolites absorbed into the serum of AVLE were identified. Proteomic analysis suggests that ferroptosis may be a key pathway, and HO-1 may be a potential target. Subsequent experimental verification showed that AVLE inhibited ferroptosis and regulated the Nrf2/HO-1 signaling pathway. Conclusion: AVLE can improve diabetic kidney disease and is closely associated with the regulation of the Nrf2/HO-1 signaling pathway, thereby alleviating renal dysfunction, fibrosis, and oxidative stress. This study provides experimental evidence for the potential application of AVLE in the prevention and treatment of diabetic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.